NCT05945823 2025-12-29
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
Taiho Oncology, Inc.
Fox Chase Cancer Center
Alliance for Clinical Trials in Oncology
Sun Yat-sen University
Northwestern University